Sodium-glucose transporter-2 inhibitor-associated severe diabetic ketoacidosis: a rare but serious complication

• 발행기관: 조선대학교 의학연구원
• 저자명: Sang Yong Kim
• 간행물 정보: 『Medical Biological Science and Engineering』제8권 제2호, 99~102쪽, 전체 4쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2025.07.31

국문 초록

Sodium-glucose transporter-2 (SGLT2) inhibitors are widely used for glycemic control in patients with type 2 diabetes mellitus (T2DM). However, these agents have been associated with an increased risk of diabetic ketoacidosis (DKA), often presenting with relatively mild hyperglycemia, known as euglycemic DKA. A 32-year-old female with a 4-year history of T2DM and major depressive disorder presented with progressive polyuria and polydipsia. Her pharmacotherapy included metformin (850 mg bid) and empagliflozin (10 mg). Initial blood gas analysis revealed severe metabolic acidosis, hyperglycemia, and markedly elevated lactate levels. Her condition worsened despite standard DKA management, necessitating continuous renal replacement therapy and mechanical ventilation. Serial arterial blood gas analyses demonstrated gradual metabolic recovery, with acidosis resolving following intensive therapy. Patients with SGLT2 inhibitor-associated DKA may experience severe metabolic acidosis requiring intensive care. Clinicians should maintain a high index of suspicion for this condition, especially in patients prescribed SGLT2 inhibitors.

목차

INTRODUCTION

CASE REPORT

DISCUSSION

REFERENCES

키워드

Sodium-glucose transporter 2 inhibitors Diabetic ketoacidosis Diabetes complications